Suresh S. Ramalingam,
Fiona Blackhall,
Maciej Krzakowski,
Carlos H. Barrios,
Keunchil Park,
Isabel Bover,
Dae Seog Heo,
Rafael Rosell,
Denis C. Talbot,
Richard Frank,
Stephen P. Letrent,
Ana Ruiz-Garcia,
Ian Taylor,
Jane Q. Liang,
Alicyn K. Campbell,
Joseph O'Connell,
Michael Boyer,
Fiona Blackhall,
Maciej Krzakowski,
Carlos H. Barrios,
Keunchil Park,
Isabel Bover,
Dae Seog Heo,
Rafael Rosell,
Denis C. Talbot,
Richard Frank,
Stephen P. Letrent,
Ana Ruiz-Garcia,
Ian Taylor,
Jane Q. Liang,
Alicyn K. Campbell,
Joseph O'Connell,
Michael Boyer,
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Ramalingam, S.S., Blackhall, F., Krzakowski, M., Barrios, C.H., Park, K., Bover, I., Seog Heo, D., Rosell, R., Talbot, D.C., Frank, R., Letrent, S.P., Ruiz-Garcia, A., Taylor, I., Liang, J.Q., Campbell, A.K., O'Connell, J., Boyer, M. J. Clin. Oncol. (2012)